Search

everythinglearnresearchcommunity

for

Search:↓

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Early baldness and little chest hair may indicate higher prostate cancer risk.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

Certain genetic variants increase the risk of aggressive prostate cancer.

Men with male pattern baldness may have a slightly higher risk of prostate cancer.

Men with baldness on the top of their head might have a small increased risk of prostate cancer.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Higher cholesterol levels increase aggressive prostate cancer risk.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Male pattern baldness may be linked to prostate cancer risk.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

More research and guidelines are needed for managing prostate cancer in people with high-risk genetic mutations.

Long-term antiandrogen use may increase aggressive prostate cancer risk.

5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.